Novartis AG has presented yet more data on Cosentyx (secukinumab) at the European League Against Rheumatism (EULAR) congress in Amsterdam which it believes will help the drug achieve a leading position in ankylosing spondylitis (AS) and psoriatic arthritis (PsA), as well as psoriasis.
In an interview with Scrip on the sidelines of EULAR, Eric Hughes, global development head of immunology, hepatology and dermatology,...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
